Genetic engineering in cancer and infectious diseases

New ways to treat diseases

Our group operates as a joint laboratory, a synergistic partnership between the University of Milan (UNIMI) and the National Institute of Molecular Genetics (INGM). This collaboration leverages the distinct strengths of both institutions to advance our research interests.

The central focus of our research is the development and adaptation of cutting-edge gene editing technologies for both fundamental laboratory investigations and translational therapeutic applications. We are dedicated to establishing innovative therapeutic interventions for a range of diseases, employing two complementary strategies: (i) the engineering of extracellular vesicles for efficient and targeted delivery of gene editing tools or variety of therapeutic proteins, and (ii) the precise manipulation of human lymphocyte activation and effector mechanisms to potentiate next-generation lymphocyte-based immunotherapies.